1625 Results (Page 24 of 65)
Rare Diseases Markets Research Reports
Japan Fragile-X Syndrome Therapeutics Market Analysis
Japan Fragile-X Syndrome Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The most typical cause of inherited learning disabilities is fragile X syndrome (FXS), an X-linked genetic disorder. The global market is driven by the higher prevalence of males than females, the transmission of the disease from one generation to the next, and the rise in patients suffering from this and other genetic disorders. Aelis Farma Sas, Alcobra Ltd, Amo Pharma Limited, Confluence Pharmaceuticals Llc, F. Hoffmann-la Roche Ltd., Marinus Pharmaceuticals, Mi.to. Technology S.r.l., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Acadia Pharmaceuticals, Advanz Pharma Corp, Boehringer Ingelheim, GlaxoSmithKline, H. Lundbeck, Janssen, Novartis, Ots.
Brazil Narcolepsy Therapeutics Market Analysis
Brazil narcolepsy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increased prevalence of narcoleptic disorders worldwide, rising stress levels, an ageing population, and growing public awareness of the variety of treatments for this condition are all predicted to have a positive impact on the market. Major global players in Narcolepsy Therapeutics Market are Avadel Pharmaceuticals Inc, Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals USA Inc.
Egypt Colorectal Cancer Drugs Market Analysis
Egypt Colorectal Cancer drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for colorectal cancer drugs is expanding due to various reasons like increase incidence and prevalence of colorectal cancer cases, increase awareness about the disease, globally ageing population. Mortality due to colorectal cancer, rising medical tourism in developing countries and benefits offered by generic medicines are other reasons. Bristol-Myer Squibb, Merck, Sanofi, Eli Lilly, Bayer are the top key market players in Global Colorectal Cancer drugs Market.
US Hunter Syndrome Therapeutics Market Analysis
US Hunter Syndrome Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Rare X-linked recessive genetic disorder MPS II (Hunter Syndrome) is brought on by changes in the iduronate-2-sulfatase gene (IDS). Due to the poor understanding of the illness, creating effective treatments for uncommon diseases can be difficult and expensive, which has a negative impact on the market for syndromes. Global Key Players in the Hunter Syndrome Therapeutics Market Include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceutical Inc., Shire (now a part of Takeda), Sanofi Genzyme, Ultragenyx Pharmaceutical Inc., Sangamo Therapeutics, Inc., RegenxBio Inc., Denali Therapeutics Inc., JCR Pharmaceuticals Co., Ltd., and ArmaGen Inc.
UK Retinal Detachment Therapeutics Market Analysis
UK Retinal Detachment Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The primary factor driving the market is the increase in retinal illnesses linked to diabetes on a global scale. Another important factor promoting industrial expansion is an increase in healthcare spending. Major global players in Retinal Detachment Therapeutics Market are MERIDIAN AG, IRIDEX Corporation, Ellex Medical, ZEISS, Millennium Surgical Corp., BVM MEDICAL LTD, Lombart Instrument, Welch Allyn, Inc., Aspen Surgical., Rudolf Riester GmbH, ONL Therapeutics, Keeler Ltd., Eyenuk, Inc., Inami & CO., Ltd., Trufocus Corporation, Imagine Eyes, HEALPROS, NeuroVision Imaging, Inc., Optos., Bausch & Lomb Incorporated, Alcon Vision LLC, HOYA Corporation, and Peek Vision Ltd.,
France Hemophilia A Drugs Market Analysis
France Hemophilia A Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Hemophilia A is rising due to increase in incidence and prevalence of disease, increase in research and development activities, patent advocacy programmes, stratergic collaborations and partnerships. A lack of or failure with regard to clotting factor VIII characterises the rare inherited bleeding condition known as haemophilia A. It is the most prevalent form of haemophilia and primarily affects men, though it can also afflict women who carry the gene mutation. Hemophilia A market development goes beyond traditional markets, with a stronger emphasis on increasing access to care in developing markets. In areas where access to specialised care and therapies may be restricted, efforts are being made to improve diagnosis, treatment infrastructure, and pricing. Some of the notable companies operating in the Hemophilia A Drugs market include BioMarin Pharmaceutical Inc, Bayer AG, Pfizer Inc., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., Shire (now part of Takeda Pharmaceutical Company Limited), CSL Behring LLC, Sanofi S.A., Grifols S.A. and Octapharma AG.
Spain X-Linked Myotubular Myopathy (XLMTM) Drugs Market Analysis
Spain X-Linked Myotubular Myopathy (XLMTM) Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for X-Linked Myotubular Myopathy (XLMTM) Drugs is growing rapidly as a result of unmet medical need for therapies of X-Linked Myotubular Myopathy (XLMTM) disease, advancements in gene therapy, Growing Awareness and Patient Advocacy about the disease, Increased Research and Collaboration between research organizations and pharmaceutical companies, supportive regulatory environments, Technological Advancements in gene sequencing and biomarker identification. Novartis Gene Therapies, Avrobio, Axovant Gene Therapies, Sarepta Therapeutics, Amicus Therapeutics, Sanofi Genzyme, Pfizer, Audentes Therapeutics are the key market players operating in global X-Linked Myotubular Myopathy (XLMTM) Drugs market.
Japan Frontotemporal Disorders Therapeutics Market Analysis
Japan Glioblastoma Multiforme Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Neurons in the frontal and temporal lobes of the brain are damaged in frontotemporal diseases (FTD), also known as frontotemporal dementia. As the patient population for FTD is growing, non-profit organisations, illness advocacy groups, and private organisations are currently concentrating on supporting treatment research. A major driver of the frontotemporal disorders treatment market growth is predicted to be the rising life expectancy rate, which is also expected to contribute to the increasing prevalence of neurological diseases among the older population. Apotex Inc., AstraZeneca plc., Auro Pharma, Johnson & Johnson, Mylan N.V., Pfizer Inc., Sanofi S.A., and Teva Pharmaceuticals USA, Inc. are just a few of the well-known worldwide and local businesses that are examined in the competitive landscape.
Brazil Neuroendocrine Tumor Therapeutics Market Analysis
Brazil neuroendocrine tumor therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for neuroendocrine tumors is being driven by an increase in the number of cases of these tumors. Major global players in this market are F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, LUPIN, Exact Sciences Corporation, Pfizer Inc., Ipsen Pharma, Advanced Accelerator Applications (a subsidiary of Novartis AG.
US Huntington's Disease Therapeutics Market Analysis
US huntington's disease therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for treating Huntington's disease is expanding due to a number of causes, including an increase in the disease's prevalence and a rise in the demand for modern drug types to treat the signs and symptoms of the disease. Some of the key players in the global Huntington's Disease Therapeutics Market include Pfizer, Inc. Alnylam Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd. Neurocrine Biosciences, Inc. Ionis Pharmaceuticals,Vertex Pharmaceuticals Incorporated (U.S.), Elekta AB (Sweden), Alterity Therapeutics (Australia) and som biotech (spain).
UK Rett Syndrome Therapeutics Market Analysis
UK Rett Syndrome Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Rett syndrome will grow over time as a result of expanding female population, rising public healthcare programme spending, and rising global healthcare expenditure. Major global players in Rett Syndrome Therapeutics Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)
France Hemophilia B Drugs Market Analysis
France Hemophilia B Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Hemophilia B is growing rapidly as a result of increasing patient awareness and diagnosis, advancements in treatment options, increasing research and development investments, stratergic collaborations and partnerships between research organizations and pharmaceutical companies. However, because Hemophilia B is less common than Hemophilia A, the market for therapies for this condition is smaller than it is for Hemophilia A. The rare genetic bleeding illness known as haemophilia B is brought on by a lack of or malfunction in the clotting factor IX. Takeda Pharmaceutical Company Limited (previously Shire), Pfizer Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, CSL Behring LLC, Sanofi S.A., Grifols S.A., Octapharma AG, and others are notable market participants.
China Acromegaly Therapeutics Market Analysis
China Acromegaly Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The prevalence and incidence of acromegaly and pituitary tumours are rising, as is global awareness of the disease. Technological advances in the development of new acromegaly medications are also key contributors to the market's growth. The high prevalence of hormonal problems, evolving lifestyles, and rising genetic disease incidence are all anticipated to fuel market expansion.Some of the key players in the global acromegaly therapeutics Market include Roche, Sanofi, GSK, Pfizer INC., Ipsen, Chiasma Inc, Validus pharmaceuticals LLC., Novartis AG, Amryt, Recordati, Sun Pharma, Crinetics Pharmaceuticals, Camurus, Ionis Pharmaceuticals , and Others.
Japan Gaucher Disease Therapeutics Market Analysis
Japan Gaucher Disease Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for gaucher disease drugs is growing rapidly as a result of rising incidence and prevalence of gaucher disease, increasing infrastructure spending for healthcare, rising acceptance rate of early diagnosis, increasing number of government initiatives to raise awareness and an increasing number of approved therapies for the treatment of Gaucher disease. Aptalis Pharma, Abbott Laboratories, Genzyme Corporation, Pfizer Inc., GlaxoSmithKline (GSK), Eli Lilly and Company, AVROBIO, Shire Human Genetic Therapies, Inc., Anthera Pharmaceuticals, Inc., Enobia Pharma Inc., BioMarin Pharmaceutical Inc., Merck Serono, Zymenex A/S, and MedPro Rx are the top key players of Gaucher Disease Therapeutics Market .
Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market Analysis
Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS) are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).
Egypt Cutaneous T-cell Lymphoma Market Analysis
Egypt Cutaneous T-cell Lymphoma Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Cutaneous T-cell Lymphoma is expanding as a result of increase in strategic investments by private as well as public agencies for Research and development of new drugs and therapies in the market , increase in product approval along with increasing manufacturing capacities, increasing trend towards adoptive therapies rather than small molecule and protein based treatment. All these factors are expected to increase the market growth. Bristol-Myers Squibb Company, Merck & Co., Novartis, Johnson and Johnson private limited, GlaxoSmithKline plc are the top key market players operating in the global cutaneous T-cell Lymphoma market.
US Hyperhidrosis Therapeutics Market Analysis
US hyperhidrosis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increase in disease incidence, particularly axillary hyperhidrosis in industrialised nations, is one of the causes driving the market for hyperhidrosis treatments. Additionally, it is projected that increasing healthcare service demand will considerably fuel market growth, along with an increase in new product releases and product approvals.The global hyperhidrosis treatment market?s major key players are AbbVie Inc. (Allergan PLC), Brickell Biotech Inc., Eli Lilly and Company (Dermira), 1315 Capital (miraDry Inc.), SweatBlock, Merz Pharma (Merz Aesthetics), Dermavant Sciences Inc. (Roivant Sciences), Advin Health Care, Dermadry Laboratories Inc., and Dermata Therapeutics Inc
France Hemophilia Market Analysis
France Hemophilia Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The ability of a person's blood to clot is impaired by haemophilia A and haemophilia B, two rare congenital lifelong bleeding disorders that can cause excessive bleeding and spontaneous bleeding into joints, which can cause joint damage and chronic pain and have a significant impact on quality of life. The rise in haemophilia prevalence, improvements in treatment technology, and supportive governmental activities for haemophilia management are all contributing factors to the market share growth for haemophilia treatments. In the "Global Hemophilia market," the following firms are described: Baxalta, CSL Behring, Pfizer, Inc., Bayer Healthcare, BioMarin Pharmaceutical, Inc., Biogen, Chugai Pharmaceutical Co., Novo Nordisk, Shire Plc., Baxter International, Inc., and Hospira Inc.
China Adrenoleukodystrophy (ALD) Therapeutics Market Analysis
China Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the China Adrenoleukodystrophy (ALD) drugs market.
Japan Glioblastoma Multiforme Therapeutics Market Analysis
Japan Glioblastoma Multiforme Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The most aggressive primary brain tumour is glioblastoma, also known as glioblastoma multiforme (GBM), which makes up for 15% of all intracranial neoplasms and 49% of malignant brain tumours. GBM is more common and has a worse prognosis as people age. It is still very difficult to increase the overall survival (OS) and progression-free survival (PFS) of GBM patients. Consequently, the GBM market has drivers. It is still very difficult to increase the overall survival (OS) and progression-free survival (PFS) of GBM patients. Global The following companies are significant players in the market: Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics, Inc., Sumitomo Dainippon Pharma Oncology, Inc., Merck & Co., Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd. (Boston Biomedical, Inc.)
Brazil Non Alcoholic Steatohepatitis (NASH) Therapeutics Market Analysis
Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A number of factors, including the rising prevalence of non-alcoholic steatohepatitis, the rising incidence of chronic illnesses linked to it, the rising adoption of sedentary lifestyles, the rising awareness of health issues, etc., have contributed to the growth of the non-alcoholic steatohepatitis market over the past few years. Major global players in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market are Intercept Pharmaceuticals, Inc. Novartis AG,Siemens Healthineers AG, AstraZeneca PLC, Galectin Therapeutics Inc., GENFIT S.A., Madrigal Pharmaceuticals, Inc., Inventiva S.A., ONE WAY LIVER, S.L., Galmed Pharmaceuticals Ltd., Cirius Therapeutics, Prometheus Laboratories Inc., BioPredictive.
Egypt Cystic Fibrosis Drugs Market Analysis
Egypt Cystic Fibrosis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Cystic Fibrosis Drugs is expanding as a result of rising incidence and prevalence of cystic fibrosis globally, existance of potential pipeline candidates, methods of early detection and treatment, growing awareness of the potential threat caused by cystic fibrosis and rising use of pharmacological therapy. Vertex Pharmaceuticals, AbbVie, Viatris, Nestl? Health Science, Teva pharmaceuticals are the top key market players operating in the global cystic fibrosis market.
US Hypertrophic Cardiomyopathy Therapeutics Market Analysis
US hypertrophic cardiomyopathy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. In addition to heart diseases, the market for therapies for hypertrophic cardiomyopathy is primarily driven by rises in the frequency of obesity and sedentary behaviour. Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., and Bayer AG are a few of the businesses now dominating the global hypertrophic cardiomyopathy therapeutics market.
UK Scleroderma Therapeutics Market Analysis
UK Scleroderma Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rapid rise in scleroderma prevalence, rising frequencies of genetic anomalies, and considerable environmental changes occurring all over the world are all predicted to accelerate market expansion.Major global players in Scleroderma Therapeutics Market are Emerald Health Pharmaceuticals, Argentis Pharmaceuticals, LLC., F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Corbus Pharmaceuticals Holdings, Inc., Boehringer Ingelheim International GmbH, Sanofi, Allergan, viDA Therapeutics Inc., Novartis AG, Active Biotech AB., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Kadmon Holdings, Inc., Johnson & Johnson Private Limited, Liminal BioSciences Inc and AstraZeneca.
France Hemostasis Products Market Analysis
France Hemostasis Products market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for hemostasis products is growing rapidly as a result of rising prevalence of cardiovascular diseases worldwide due to adoption of unhealthy lifestyle, consumption of unhealthy food products and rising illnesses among the population, rising medical tourism, higher investments by government in research and development of hemostasis products, huge base of geriatric population coupled with large number of blood disorders patient population, increasing demand for minimally invasive surgeries, adoption of advanced hemostasis products by patients . Abbott Laboratories, Baxter International, CSL Behring, Hem Con Medical Technologies, Grifols, Johnson & Johnson, Medtronic, Pfizer, integra Life Sciences Corporation, C. R. Bard, Inc. are the key market players operating in global hemostasis products market.
